Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1193–1197. doi: 10.1128/aac.33.8.1193

Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.

S R Smith 1, J Cheesbrough 1, R Spearing 1, J M Davies 1
PMCID: PMC172623  PMID: 2529814

Abstract

In 72 episodes of suspected or proven Hickman-catheter-associated infection occurring in 59 patients with various hematological disorders, patients were assigned to treatment with either vancomycin or teicoplanin in a randomized nonblinded prospective study. Of 60 episodes evaluable for response, 28 were treated with vancomycin and 32 were treated with teicoplanin. Sixteen infective episodes were microbiologically documented in the vancomycin group, and twenty-one were microbiologically documented in the teicoplanin group. Microbiologically and clinically documented infections treated with vancomycin had an 80% response rate, compared with a 69% response rate for those treated with teicoplanin (P = 0.316). Adverse events occurred in nine (25%) of the episodes in the vancomycin group, compared with three (8%) in the teicoplanin group (P = 0.044). Teicoplanin may provide an effective alternative to vancomycin in the treatment of Hickman-catheter-associated infection in patients with hematological malignancies.

Full text

PDF
1193

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahm J. L., Mullen J. L. A prospective study of prolonged central venous access in leukemia. JAMA. 1982 Dec 3;248(21):2868–2873. [PubMed] [Google Scholar]
  2. Blacklock H. A., Pillai M. V., Hill R. S., Matthews J. R., Clarke A. G., Wade J. F. Use of modified subcutaneous right-atrial catheter for venous access in leukaemic patients. Lancet. 1980 May 10;1(8176):993–994. doi: 10.1016/s0140-6736(80)91436-1. [DOI] [PubMed] [Google Scholar]
  3. Calain P., Krause K. H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. doi: 10.1093/infdis/155.2.187. [DOI] [PubMed] [Google Scholar]
  4. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galanakis N., Giamarellou H., Vlachogiannis N., Dendrinos C., Daikos G. K. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):130–134. doi: 10.1007/BF01963065. [DOI] [PubMed] [Google Scholar]
  6. Garrelts J. C., Peterie J. D. Vancomycin and the "red man's syndrome". N Engl J Med. 1985 Jan 24;312(4):245–245. [PubMed] [Google Scholar]
  7. Harding I., Garaud J. J. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):93–103. doi: 10.1093/jac/21.suppl_a.93. [DOI] [PubMed] [Google Scholar]
  8. Heimbach D. M., Ivey T. D. Technique for placement of a permanent home hyperalimentation catheter. Surg Gynecol Obstet. 1976 Oct;143(4):634–636. [PubMed] [Google Scholar]
  9. Hickman R. O., Buckner C. D., Clift R. A., Sanders J. E., Stewart P., Thomas E. D. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979 Jun;148(6):871–875. [PubMed] [Google Scholar]
  10. Hiemenz J., Skelton J., Pizzo P. A. Perspective on the management of catheter-related infections in cancer patients. Pediatr Infect Dis. 1986 Jan-Feb;5(1):6–11. doi: 10.1097/00006454-198601000-00002. [DOI] [PubMed] [Google Scholar]
  11. Karp J. E., Dick J. D., Angelopulos C., Charache P., Green L., Burke P. J., Saral R. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986 Aug;81(2):237–242. doi: 10.1016/0002-9343(86)90257-3. [DOI] [PubMed] [Google Scholar]
  12. Kirby W. M. Vancomycin therapy of severe staphylococcal infections. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):73–78. doi: 10.1093/jac/14.suppl_d.73. [DOI] [PubMed] [Google Scholar]
  13. Larson E. B., Wooding M., Hickman R. O. Infectious complications of right atrial catheters used for venous access in patients receiving intensive chemotherapy. Surg Gynecol Obstet. 1981 Sep;153(3):369–373. [PubMed] [Google Scholar]
  14. Lewis P., Garaud J. J., Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):61–67. doi: 10.1093/jac/21.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  15. Lowder J. N., Lazarus H. M., Herzig R. H. Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. Arch Intern Med. 1982 Aug;142(8):1456–1459. [PubMed] [Google Scholar]
  16. Lowy F. D., Hammer S. M. Staphylococcus epidermidis infections. Ann Intern Med. 1983 Dec;99(6):834–839. doi: 10.7326/0003-4819-99-6-834. [DOI] [PubMed] [Google Scholar]
  17. McNicol P. J., Ronald A. R. The plasmids of Haemophilus ducreyi. J Antimicrob Chemother. 1984 Dec;14(6):561–564. [PubMed] [Google Scholar]
  18. Mellor J. A., Kingdom J., Cafferkey M., Keane C. T. Vancomycin toxicity: a prospective study. J Antimicrob Chemother. 1985 Jun;15(6):773–780. doi: 10.1093/jac/15.6.773. [DOI] [PubMed] [Google Scholar]
  19. Menichetti F., Del Favero A., Bucaneve G., Aversa F., Baldelli F., Felicini R., Terenzi A., Pauluzzi S. Teicoplanin in empirical combined antibiotic therapy of bacteraemias in bone marrow transplant patients. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):105–111. doi: 10.1093/jac/21.suppl_a.105. [DOI] [PubMed] [Google Scholar]
  20. Patton K. R., Beg A., Felmingham D., Ridgway G. L., Grüneberg R. N. Determination of teicoplanin concentration in serum using a bioassay technique. Drugs Exp Clin Res. 1987;13(9):547–550. [PubMed] [Google Scholar]
  21. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  22. Press O. W., Ramsey P. G., Larson E. B., Fefer A., Hickman R. O. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984 Jul;63(4):189–200. doi: 10.1097/00005792-198407000-00001. [DOI] [PubMed] [Google Scholar]
  23. Reed W. P., Newman K. A., de Jongh C., Wade J. C., Schimpff S. C., Wiernik P. H., McLaughlin J. S. Prolonged venous access for chemotherapy by means of the Hickman catheter. Cancer. 1983 Jul 1;52(1):185–192. doi: 10.1002/1097-0142(19830701)52:1<185::aid-cncr2820520134>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  24. Rubin M., Hathorn J. W., Marshall D., Gress J., Steinberg S. M., Pizzo P. A. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988 Jan;108(1):30–35. doi: 10.7326/0003-4819-108-1-30. [DOI] [PubMed] [Google Scholar]
  25. Rubin R. H. Empiric antibacterial therapy in granulocytopenia induced by cancer chemotherapy. Ann Intern Med. 1988 Jan;108(1):134–136. doi: 10.7326/0003-4819-108-1-134. [DOI] [PubMed] [Google Scholar]
  26. Smith C. R., Lipsky J. J., Laskin O. L., Hellmann D. B., Mellits E. D., Longstreth J., Lietman P. S. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–1109. doi: 10.1056/NEJM198005153022002. [DOI] [PubMed] [Google Scholar]
  27. Stille W., Sietzen W., Dieterich H. A., Fell J. J. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):69–79. doi: 10.1093/jac/21.suppl_a.69. [DOI] [PubMed] [Google Scholar]
  28. Wade J. C., Schimpff S. C., Newman K. A., Wiernik P. H. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982 Oct;97(4):503–508. doi: 10.7326/0003-4819-97-4-503. [DOI] [PubMed] [Google Scholar]
  29. Webster A., Russell S. J., Souhami R. L., Richards J. D., Goldstone A. H., Grüneberg R. N. Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. J Hosp Infect. 1987 Jul;10(1):77–82. doi: 10.1016/0195-6701(87)90036-3. [DOI] [PubMed] [Google Scholar]
  30. Williams A. H., Grüneberg R. N. Teicoplanin. J Antimicrob Chemother. 1984 Nov;14(5):441–445. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES